| Name | Title | Contact Details |
|---|
Zawyer Sports & Entertainment brings sports & your brand to life. Follow our family brands, Jacksonville Icemen, Community First Igloo, Savannah Ghost Pirates, Ghost Pirates Ice, Atlanta Gladiators, Allen Americans, Tahoe Knight Monsters, Gastonia Baseball Club, and 32 Degrees Marketing.
PetVet Dx is a therapeutic management company focusing on delivering affordable, accurate, and rapid diagnostics with cutting-edge molecular technology and pharmaceuticals for veterinarians, farmers, and pet owners.
BG Products, Inc. is an international automotive maintenance services company based in Wichita, Kansas. Founded in July 1971 by a group of automotive entrepreneurs, the company specializes in high-quality maintenance products and value-added services for vehicles. BG Products has grown significantly over the years, establishing a global presence with operations in China, Australia, and Canada, and employing around 375 people. The company offers a wide range of automotive maintenance products, including fuel and oil additives, transmission fluids, engine maintenance products, and air quality solutions. BG Products is recognized for its innovative approach, being the first to market with several solutions tailored to emerging automotive technologies. Their specialized services include transmission fluid exchanges, fuel system cleaning, and maintenance for hybrid-electric vehicles. BG Products distributes its offerings through professional automotive service facilities, ensuring a premium positioning in the market.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.